Sign in

You're signed outSign in or to get full access.

Alta Partners Management Company, L.P.

CIK:0002054419
Venture Capital
$42M AUM
2 holdings
Jackson, WY, United States
Founded:1996
Latest filing:Jun 30, 2025

Alta Partners Management Company, L.P. is a venture capital and investment management firm headquartered in Jackson, Wyoming. Founded in 1996, Alta Partners specializes in investments in the healthcare and life sciences sectors, supporting entrepreneurs in building high-impact healthcare companies. The firm offers decades of industry experience and primarily serves startups and growth-stage companies in the United States healthcare ecosystem. The employee count is not publicly available.

Investment Strategy

Alta Partners focuses on venture capital investments in innovative companies within the healthcare and life sciences sectors. Its strategy centers on identifying and partnering with entrepreneurs to build companies developing novel therapies, technologies, and platforms that address significant unmet medical needs. The firm typically targets early-stage and growth-stage investments, leveraging deep sector expertise and an extensive industry network to drive value creation.

Latest 13F Filing Activity

Alta Partners Management Company, L.P. filed their most recent 13F report on Jun 30, 2025 disclosing 2 equity positions with a total 13F market value of $42M. The fund increased holdings in Tyra Biosciences Inc., Vir Biotechnology Inc.. Alta Partners Management Company, L.P. reduced exposure to Vir Biotechnology Inc., Tyra Biosciences Inc..

Top Buys
T
TYRATYRA BIOSCIENCES INC
+$1.1M
V
VIRVIR BIOTECHNOLOGY INC
-$682.4K
Top Sells
T
TYRATYRA BIOSCIENCES INC
+$1.1M
V
VIRVIR BIOTECHNOLOGY INC
-$682.4K

Top Holdings

T
TYRATYRA BIOSCIENCES INC
+93.8%$39.0M
V
VIRVIR BIOTECHNOLOGY INC
+6.2%$2.6M

Equity Positions (2)

TickerSecurityWeightMarket ValueSharesAvg CostPriceChange (QoQ)
TYRA BIOSCIENCES INC93.82%$39.0M4,080,296$13.90$9.57+$1.1M
VIR BIOTECHNOLOGY INC6.18%$2.6M509,917$7.28$5.04-$682.4K

Industry Allocation

PHARMACEUTICAL PREPARATIONS
+95.1%
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
+4.9%